The use of commercial fibrin glue in dermal replacement material reduces angiogenic and lymphangiogenic gene and protein expression in vitro.

Adipose-derived stem cells Enzym-linked Immunosorbent Assay Fibrin glue Hypoxia-inducible factor 1-alpha Lymphatic endothelial cells Multiplex-RT-PCR Vascular Endothelial Growth Factor angiogenesis gene and protein expression human umbilical vein endothelial cells lymphangiogenesis

Journal

Journal of biomaterials applications
ISSN: 1530-8022
Titre abrégé: J Biomater Appl
Pays: England
ID NLM: 8813912

Informations de publication

Date de publication:
05 2023
Historique:
medline: 29 5 2023
pubmed: 21 4 2023
entrez: 21 04 2023
Statut: ppublish

Résumé

Commercial fibrin glue is increasingly finding its way into clinical practice in surgeries to seal anastomosis, and initiate hemostasis or tissue repair. Human biological glue is also being discussed as a possible cell carrier. To date, there are only a few studies addressing the effects of fibrin glue on the cell-molecular level. This study examines the effects of fibrin glue on angiogenesis and lymphangiogenesis, as well as adipose-derived stem cells (ASCs) with a focus on gene and protein expression in scaffolds regularly used for tissue engineering approaches. Collagen-based dermal regeneration matrices (DRM) were seeded with human umbilical vein endothelial cells (HUVEC), human dermal lymphatic endothelial cells (LECs), or adipose-derived stem cells (ASC) and fixed with or without fibrin glue according to the experimental group. Cultures were maintained for 1 and 7 days. Finally, angiogenic and lymphangiogenic gene and protein expression were measured with special regard to subtypes of vascular endothelial growth factor (VEGF) and corresponding receptors using Multiplex-qPCR and ELISA assays. In addition, the hypoxia-induced factor 1-alpha (HIF1a) mediated intracellular signaling pathways were included in assessments to analyze a hypoxic encapsulating effect of fibrin polymers. All cell types reacted to fibrin glue application with an alteration of gene and protein expression. In particular, vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor B (VEGFB), vascular endothelial growth factor C (VEGFC), vascular endothelial growth receptor 1 (VEGFR1/FLT1), vascular endothelial growth receptor 2 (VEGFR2/KDR), vascular endothelial growth receptor 3 (VEGFR3/FLT4) and Prospero Homeobox 1 (PROX1) were depressed significantly depending on fibrin glue. Especially short-term fibrin effect led to a continuous downregulation of respective gene and protein expression in HUVECs, LECs, and ASCs. Our findings demonstrate the impact of fibrin glue application in dermal regeneration with special regard to angiogenesis and lymphangiogenesis. In particular, a short fibrin treatment of 24 hours led to a decrease in gene and protein levels of LECS, HUVECs, and ASCs. In contrast, the long-term application showed less effect on gene and protein expressions. Therefore, this work demonstrated the negative effects of fibrin-treated cells in tissue engineering approaches and could affect wound healing during dermal regeneration.

Sections du résumé

BACKGROUND
Commercial fibrin glue is increasingly finding its way into clinical practice in surgeries to seal anastomosis, and initiate hemostasis or tissue repair. Human biological glue is also being discussed as a possible cell carrier. To date, there are only a few studies addressing the effects of fibrin glue on the cell-molecular level. This study examines the effects of fibrin glue on angiogenesis and lymphangiogenesis, as well as adipose-derived stem cells (ASCs) with a focus on gene and protein expression in scaffolds regularly used for tissue engineering approaches.
METHODS
Collagen-based dermal regeneration matrices (DRM) were seeded with human umbilical vein endothelial cells (HUVEC), human dermal lymphatic endothelial cells (LECs), or adipose-derived stem cells (ASC) and fixed with or without fibrin glue according to the experimental group. Cultures were maintained for 1 and 7 days. Finally, angiogenic and lymphangiogenic gene and protein expression were measured with special regard to subtypes of vascular endothelial growth factor (VEGF) and corresponding receptors using Multiplex-qPCR and ELISA assays. In addition, the hypoxia-induced factor 1-alpha (HIF1a) mediated intracellular signaling pathways were included in assessments to analyze a hypoxic encapsulating effect of fibrin polymers.
RESULTS
All cell types reacted to fibrin glue application with an alteration of gene and protein expression. In particular, vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor B (VEGFB), vascular endothelial growth factor C (VEGFC), vascular endothelial growth receptor 1 (VEGFR1/FLT1), vascular endothelial growth receptor 2 (VEGFR2/KDR), vascular endothelial growth receptor 3 (VEGFR3/FLT4) and Prospero Homeobox 1 (PROX1) were depressed significantly depending on fibrin glue. Especially short-term fibrin effect led to a continuous downregulation of respective gene and protein expression in HUVECs, LECs, and ASCs.
CONCLUSION
Our findings demonstrate the impact of fibrin glue application in dermal regeneration with special regard to angiogenesis and lymphangiogenesis. In particular, a short fibrin treatment of 24 hours led to a decrease in gene and protein levels of LECS, HUVECs, and ASCs. In contrast, the long-term application showed less effect on gene and protein expressions. Therefore, this work demonstrated the negative effects of fibrin-treated cells in tissue engineering approaches and could affect wound healing during dermal regeneration.

Identifiants

pubmed: 37082911
doi: 10.1177/08853282231171681
pmc: PMC10226008
doi:

Substances chimiques

Vascular Endothelial Growth Factor A 0
Vascular Endothelial Growth Factor B 0
Fibrin Tissue Adhesive 0
Vascular Endothelial Growth Factor C 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1858-1873

Références

Neurosurgery. 2007 Sep;61(3 Suppl):E51; discussion E51
pubmed: 17876220
Int J Mol Sci. 2020 Jul 21;21(14):
pubmed: 32708334
Tissue Cell. 2005 Oct;37(5):339-48
pubmed: 16009388
Methods. 2008 Jun;45(2):115-20
pubmed: 18593609
Blood Rev. 2007 May;21(3):131-42
pubmed: 17208341
Adv Clin Exp Med. 2018 Jun;27(6):857-862
pubmed: 29938935
Int J Retina Vitreous. 2021 Apr 15;7(1):33
pubmed: 33858517
Ann Otol Rhinol Laryngol. 2003 May;112(5):410-4
pubmed: 12784978
Front Bioeng Biotechnol. 2020 Oct 06;8:577204
pubmed: 33123516
Biomed Res Int. 2021 Apr 10;2021:6695663
pubmed: 33937411
Am J Surg. 2001 Aug;182(2 Suppl):21S-28S
pubmed: 11566473
Plast Reconstr Surg. 2009 Sep;124(3):989-992
pubmed: 19730324
Wound Repair Regen. 2014 May-Jun;22(3):313-25
pubmed: 24844331
Clin Dermatol. 1994 Jan-Mar;12(1):89-93
pubmed: 8180949
J Tissue Eng Regen Med. 2019 Mar;13(3):359-368
pubmed: 30515986
Acta Biomater. 2021 May;126:132-143
pubmed: 33753313
Acta Cir Bras. 2019 Oct 14;34(8):e201900801
pubmed: 31618401
ISRN Surg. 2014 Mar 04;2014:203943
pubmed: 24729902
Acta Biomater. 2014 Jun;10(6):2712-7
pubmed: 24406198
Phys Chem Chem Phys. 2007 Mar 21;9(11):1291-306
pubmed: 17347701
Exp Cell Res. 2014 Mar 10;322(1):1-11
pubmed: 24378385
Biomaterials. 1995 Aug;16(12):891-903
pubmed: 8562777
Biores Open Access. 2012 Jan;1(1):34-40
pubmed: 23515363
Ann Biomed Eng. 2015 Mar;43(3):657-80
pubmed: 25537688
Acta Biomed. 2003;74 Suppl 2:21-5
pubmed: 15055028
Adv Protein Chem. 2005;70:247-99
pubmed: 15837518
Tissue Eng Part B Rev. 2008 Jun;14(2):199-215
pubmed: 18544016
Tech Coloproctol. 2006 Oct;10(3):208-14
pubmed: 16969615
Theranostics. 2021 Apr 30;11(13):6616-6631
pubmed: 33995680
Plast Reconstr Surg. 2011 Jun;127(6):2381-2390
pubmed: 21311390
Stem Cells Int. 2018 Dec 19;2018:1353085
pubmed: 30662467
Tissue Eng Part A. 2008 Aug;14(8):1331-40
pubmed: 18601588
Plast Reconstr Surg. 2007 Jan;119(1):95-103
pubmed: 17255661
Orthop Clin North Am. 1988 Jan;19(1):187-99
pubmed: 2447544
Transfus Apher Sci. 2021 Aug;60(4):103144
pubmed: 33893027
J Appl Oral Sci. 2015 Nov-Dec;23(6):623-8
pubmed: 26814464
Br J Surg. 2019 Feb;106(3):165-173
pubmed: 30724361
Acta Biomater. 2015 Mar;15:39-47
pubmed: 25536030
Biomed Mater. 2015 Jun 24;10(3):035013
pubmed: 26107105
Cochrane Database Syst Rev. 2016 Dec 02;12:CD011308
pubmed: 27911983
Curr Top Med Chem. 2019;19(32):2985-2990
pubmed: 31721704
Eye (Lond). 2016 Oct;30(10):1389-1394
pubmed: 27367746
Am J Transl Res. 2019 May 15;11(5):2866-2876
pubmed: 31217860
Transfus Apher Sci. 2008 Feb;38(1):15-23
pubmed: 18282807
Plast Reconstr Surg. 2015 Dec;136(6):1216-1225
pubmed: 26267401
J Biomater Appl. 2017 Mar;31(8):1215-1224
pubmed: 28181448

Auteurs

Benedikt Fuchs (B)

Department of Hand, Plastic and Aesthetic Surgery, LMU, Munich, Germany.

Alexandra Birt (A)

Department of Hand, Plastic and Aesthetic Surgery, LMU, Munich, Germany.

Nicholas Moellhoff (N)

Department of Hand, Plastic and Aesthetic Surgery, LMU, Munich, Germany.

Constanze Kuhlmann (C)

Department of Hand, Plastic and Aesthetic Surgery, LMU, Munich, Germany.

Riccardo Giunta (R)

Department of Hand, Plastic and Aesthetic Surgery, LMU, Munich, Germany.

Paul Severin Wiggenhauser (PS)

Department of Hand, Plastic and Aesthetic Surgery, LMU, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH